Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer

doi:10.3748/wjg.v26.i8.804

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7348)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series.

Item

Count

PDF

544

WORD

141

HTML

4974

Figures (1-7)

226

Sum=5885

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

726

Download

737

Sum=1463

Feb 28, 2020 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Feb 28, 2020; 26(8): 804-817
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.804

Full Size Figure Download Figure

Figure 4 Liver cancer patients were subjected to examination of the overall survival, progression-free survival and relapse-free survival rates in orosomucoid high and low patient groups. A and B: Overall survival rate was determined to study the effect of orosomucoid 1 (ORM1) and ORM2 on liver cancer patients. C and D: Progression-free survival rate analysis was used to evaluate the role of ORM1 and ORM2 in liver cancer patients. E and F: High and low ORM patient groups were studied to determine relapse-free survival rates. OS: Overall survival; PFS: Progression-free survival; RFS: Relapse-free survival.

Citation: Zhu HZ, Zhou WJ, Wan YF, Ge K, Lu J, Jia CK. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World J Gastroenterol 2020; 26(8): 804-817
URL: https://www.wjgnet.com/1007-9327/full/v26/i8/804.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i8.804